Transcend Capital Advisors LLC Has $1.24 Million Stake in Zoetis Inc. (NYSE:ZTS)

Transcend Capital Advisors LLC grew its stake in Zoetis Inc. (NYSE:ZTS) by 259.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,618 shares of the company’s stock after buying an additional 5,498 shares during the period. Transcend Capital Advisors LLC’s holdings in Zoetis were worth $1,241,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ZTS. Bradley Foster & Sargent Inc. CT boosted its position in Zoetis by 10.1% during the fourth quarter. Bradley Foster & Sargent Inc. CT now owns 216,629 shares of the company’s stock worth $35,295,000 after purchasing an additional 19,889 shares during the period. Investors Asset Management of Georgia Inc. GA ADV boosted its holdings in shares of Zoetis by 5.0% during the 4th quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 2,120 shares of the company’s stock worth $345,000 after buying an additional 101 shares during the period. Suncoast Equity Management acquired a new position in Zoetis in the 4th quarter valued at $1,917,000. FDx Advisors Inc. grew its stake in Zoetis by 16.7% in the 4th quarter. FDx Advisors Inc. now owns 1,682 shares of the company’s stock valued at $274,000 after buying an additional 241 shares during the last quarter. Finally, Nicholson Wealth Management Group LLC raised its holdings in Zoetis by 137.5% in the 4th quarter. Nicholson Wealth Management Group LLC now owns 7,875 shares of the company’s stock worth $1,283,000 after acquiring an additional 4,559 shares during the period. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Piper Sandler dropped their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Barclays increased their price objective on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Finally, Morgan Stanley dropped their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $214.90.

Zoetis Trading Up 1.9 %

Shares of ZTS stock opened at $160.39 on Friday. The firm has a fifty day moving average of $166.51 and a 200-day moving average of $178.04. The stock has a market cap of $71.82 billion, a price-to-earnings ratio of 29.32, a P/E/G ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.25%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.